US FDA accepts Sirion's filing for ocular herpes drug
This article was originally published in Scrip
Executive Summary
The US FDAhas accepted for review Sirion Therapeutics' NDA for ganciclovir ophthalmic gel 0.15% as a treatment for herpetic keratitis, an ocular disease caused by the herpes simplex virus.